Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Aysun Karabulut, Semra Demirlenk & Osman Şevket. (2012) Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome. Gynecological Endocrinology 28:4, pages 245-248.
Read now
Read now
Johan Verhaeghe. (2010) Hormonal contraception in women with the metabolic syndrome: A narrative review. The European Journal of Contraception & Reproductive Health Care 15:5, pages 305-313.
Read now
Read now
Feridun Karakurt, Ilknur Inegol Gumus, Nuket Bavbek, Ayse Kargili, Cemile Koca, Yusuf Selcoki, Mustafa Ozbek, Ali Kosar & Ali Akcay. (2008) Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Gynecological Endocrinology 24:9, pages 491-497.
Read now
Read now
Articles from other publishers (17)
Mingyu Liao, Xing Li, Hao Zhang, Ling Zhou, Liu Shi, Weixin Li, Rufei Shen, Guiliang Peng, Huan Zhao, Jiaqing Shao, Xiujie Wang, Zheng Sun, Hongting Zheng & Min Long. (2023) Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial. Endocrine.
Crossref
Crossref
Rui-Lin Ma, Yan Deng, Yan-Fang Wang, Shi-Yang Zhu, Xue-Song Ding & Ai-Jun Sun. (2021) Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. Chinese Medical Journal 134:23, pages 2882-2889.
Crossref
Crossref
Mohamed Abdel-Maboud, Amr Menshawy, Elfatih A. Hasabo, Mohamed Ibrahim Abdelraoof, Mohamed Alshandidy, Muhammad Eid, Esraa Menshawy, Oumaima Outani & Ahmed Menshawy. (2021) The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: A network meta-analysis of 101 randomized trials. PLOS ONE 16:7, pages e0254412.
Crossref
Crossref
Yogamaya D Prabhu, Abilash Valsala Gopalakrishnan & Selvaraj Mohana Roopan. 2021. Phytopharmaceuticals. Phytopharmaceuticals
287
300
.
M. Amiri, M. Rahmati, M. Hedayati, F. Nahidi & F. Ramezani Tehrani. (2020) Effects of oral contraceptives on serum concentrations of adipokines and adiposity indices of women with polycystic ovary syndrome: a randomized controlled trial. Journal of Endocrinological Investigation 44:3, pages 567-580.
Crossref
Crossref
Qiu-Yi Wang, Yong Song, Wei Huang, Li Xiao, Qiu-Shi Wang & Gui-Mei Feng. (2016) Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders. Chinese Medical Journal 129:8, pages 883-890.
Crossref
Crossref
Ali Cenk Ozay, Ozlen Emekci Ozay, Recep Emre Okyay, Erkan Cagliyan, Tuncay Kume & Bulent Gulekli. (2016) Different Effects of Myoinositol plus Folic Acid versus Combined Oral Treatment on Androgen Levels in PCOS Women. International Journal of Endocrinology 2016, pages 1-8.
Crossref
Crossref
Supatra Leelaphiwat, Theerayut Jongwutiwes, Srithean Lertvikool, Chotika Tabcharoen, Matchuporn Sukprasert, Sasivimol Rattanasiri & Sawaek Weerakiet. (2014) Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: A randomized controlled trial. Journal of Obstetrics and Gynaecology Research 41:3, pages 402-410.
Crossref
Crossref
Miranda G. Mes-Krowinkel, Yvonne V. Louwers, Annemarie G.M.G.J. Mulders, Frank H. de Jong, Bart C.J.M. Fauser & Joop S.E. Laven. (2014) Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients. Fertility and Sterility 101:6, pages 1757-1765.e1.
Crossref
Crossref
S.S. Lim, M.J. Davies, R.J. Norman & L.J. Moran. (2012) Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 18:6, pages 618-637.
Crossref
Crossref
Alexandra Bargiota & Evanthia Diamanti-Kandarakis. (2012) The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Therapeutic Advances in Endocrinology and Metabolism 3:1, pages 27-47.
Crossref
Crossref
I. J. Halperin, S. Sujana Kumar, D. F. Stroup & S. E. Laredo. (2010) The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Human Reproduction 26:1, pages 191-201.
Crossref
Crossref
E. Diamanti-Kandarakis, E. Kandaraki, C. Christakou & D. Panidis. (2009) The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. Obesity Reviews 10:4, pages 431-441.
Crossref
Crossref
Suna ?zdemir, H?seyin G?rkemli, Kazim Gezgin?Mustafa ?zdemir & Aysel Kiyici. (2008) Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. International Journal of Gynecology & Obstetrics 103:1, pages 44-49.
Crossref
Crossref
H.E. Westerveld, M. Hoogendoorn, A.W.F. de Jong, A.J. Goverde, B.C.J.M. Fauser & G.M. Dallinga-Thie. (2008) Cardiometabolic abnormalities in the polycystic ovary syndrome: Pharmacotherapeutic insights. Pharmacology & Therapeutics 119:3, pages 223-241.
Crossref
Crossref
Manuel Luque-Ramírez, Francisco Álvarez-Blasco, José I. Botella-Carretero, Elena Martínez-Bermejo, Miguel A. Lasunción & Héctor F. Escobar-Morreale. (2007)
Comparison of Ethinyl-Estradiol Plus Cyproterone Acetate
Versus
Metformin Effects on Classic Metabolic Cardiovascular Risk Factors in Women with the Polycystic Ovary Syndrome
. The Journal of Clinical Endocrinology & Metabolism 92:7, pages 2453-2461.
Crossref
Crossref
Rhoda H. Cobin. (2005) Polycystic Ovarian Syndrome and Insulin Resistance: Implications for Estrogen Use in Premenopausal and Postmenopausal Women. Metabolic Syndrome and Related Disorders 3:3, pages 259-269.
Crossref
Crossref